Drug
Latanoprost clinical trials
Also written Xalatan, T2345 and PhXA41.
- studies test it
- 99
- open now
- 5
- in phase 3
- 19
- first study started
- 1992
Keep track of what changes. Save the Latanoprost studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
96 studies that test it; most in 2009 (10)
| Year | Studies |
|---|---|
| 1992 | 2 |
| 1993 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 4 |
| 2005 | 7 |
| 2006 | 7 |
| 2007 | 6 |
| 2008 | 9 |
| 2009 | 10 |
| 2010 | 8 |
| 2011 | 6 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 3
- Phase 2
- 26
- Phase 3
- 19
- Phase 4
- 36
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
- Glaucoma
- 31
Who runs them
Industry 52 · Other 47
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (13) · Mati Therapeutics Inc. (8) · Allergan (6) · Pfizer (4) · Alcon Research (4) · Laboratoires Thea (3) · Zagazig University (2) · University of Nebraska (2)
Often tested with
Tested in the same studies.
Timolol (14) · Travoprost (14) · Bimatoprost (10) · Dorzolamide (7) · Brimonidine (5) · Xalacom (3) · Tafluprost (2) · Dorzolamide-timolol combination (2)
Studies
Open first, then newest update. How each study uses Latanoprost is read from its arms, and is right about nine times in ten.
Testing it · 99
- Optic Nerve Head Strain in Non-glaucoma SubjectsRecruitingEarly Phase 1Johns Hopkins UniversityNCT07425535Written as Latanoprost (0.005%)
- Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma SuspectsRecruitingPhase 4University of Maryland, BaltimoreNCT04401982Written as Latanoprost (0.005%)
- 0.005% Latanoprost Gel for Nonsegmental VitiligoNot yet recruitingPhase 2Universitas PadjadjaranNCT07016113Written as 0.005% latanoprost gel
- Evaluation of Latanoprost Combined With Fractional Erbium- YAG LaserRecruitingPhase 1/2EgymedicalpediaNCT06239324Written as Latanoprost
- Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet CellsRecruitingPhase 4Rigshospitalet, DenmarkNCT04957329Written as Xalatan
- Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia AreataCompletedNot applicableTanta UniversityNCT07757867Written as Latanoprost
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure VarianceCompletedPhase 4Ohio State UniversityNCT04412096Written as Latanoprost 0.005% Ophthalmic Solution
- Stop Retinal Ganglion Cell Dysfunction StudyTerminatedPhase 3University of MiamiNCT02390284Written as Latanoprost
- Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Nicox Ophthalmics, Inc.NCT04445519Written as Latanoprost 0.005% (initial phase of trial)
- Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin TartrateCompletedEarly Phase 1Zagazig UniversityNCT06730516Written as Latanoprost (Xalatan)
- Effect of Latanoprost on Optic Nerve PerfusionCompletedPhase 1Zagazig UniversityNCT06629129Written as Latanoprost (0.005%)
- Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionCompletedPhase 2Laboratoires TheaNCT01494753Written as T2345
- Comparison of Latanoprost Vs. TimololTerminatedPhase 2University of NebraskaNCT00579969Written as Latanoprost
- Circadian Rhythms of Aqueous Humor Dynamics in HumansCompletedPhase 2University of NebraskaNCT00572936Written as Latanoprost
- Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory EvaluationActive, not recruitingPhase 4Shaimaa Fawzy Abdel-rady Abdel-latifNCT04811326Written as Latanoprost
- Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.CompletedPhase 2/3South Valley UniversityNCT05513924Written as Latanoprost 0.005% Ophthalmic Solution
- Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical FormulationStatus unknownEarly Phase 1Aneira Pharma, Inc.NCT05790941Written as Latanoprost and Minoxidil
- Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.Status unknownPhase 4Uzoma Chinyei JoanNCT05606796Written as Latanoprost 0.005% Ophthalmic Solution
- A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).CompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00383019Written as Xalatan
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329CompletedPhase 2PfizerNCT00934089Written as latanoprost
See all 99 studies that test Latanoprost →
Given in every arm · 13 — Latanoprost is usual care beside what is tested
- Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionActive, not recruitingPhase 2PolyActiva Pty LtdNCT06964191Written as Latanoprost 0.005% Ophthalmic Solution
- Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle GlaucomaCompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT04405245Written as Latanoprost ophthalmic solution
- A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 1Hoffmann-La RocheNCT03293992Written as Latanoprost 0.005%
- Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension SubjectsCompletedPhase 4AllerganNCT00735449Written as latanoprost 0.005%
- Microneedling and Latanoprost in Acrofacial VitiligoStatus unknownPhase 2/3Sohag UniversityNCT03611348Written as Latanoprost
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).CompletedPhase 1Hoffmann-La RocheNCT02622334Written as Latanoprost
- A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaCompletedPhase 2Inotek Pharmaceuticals CorporationNCT01917383Written as Latanoprost
- Safety Study of Latanoprost Slow Release InsertTerminatedPhase 1Daniel MooreNCT01180062Written as Latanoprost
- Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyCompletedPhase 4Alcon ResearchNCT01263444Written as Habitual prostaglandin monotherapy
- AR-12286 in Combination With LatanoprostCompletedPhase 2Aerie PharmaceuticalsNCT01302249Written as Latanoprost 0.005%
- A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a ProstaglandinCompletedPhase 4Alcon ResearchNCT00759941Written as Latanoprost 0.005% ophthalmic solution (Xalatan)
- A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionCompletedPhase 4AllerganNCT01525173Written as latanoprost 0.005% ophthalmic solution
- Adjunctive Study of AL-37807 Ophthalmic SuspensionCompletedPhase 2Alcon ResearchNCT00620256Written as Latanoprost ophthalmic solution
As the comparator · 64 — what is tested is compared with Latanoprost
- Rocklatan vs Latanoprost Post-DSLTRecruitingPhase 4Eye Centers of Southeast TexasNCT07465913Written as Latanoprost 0.005% Ophthalmic Solution
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension PatientsRecruitingPhase 4Mayo ClinicNCT07325240Written as Latanoprost 0.005% Ophthalmic Solution
- Efficacy of Simbrinza and Rocklatan vs Cosopt and LatanoprostRecruitingPhase 4Prairie Eye CenterNCT06883123Written as Latanoprost 0.005% Ophthalmic Solution
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2/3Qlaris Bio, Inc.NCT07354516Written as Latanoprost (0.005%)
- A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaActive, not recruitingPhase 3Santen Pharmaceutical Co., Ltd.NCT06666855Written as Latanoprost
- Next Generation RocklatanCompletedPhase 2Alcon ResearchNCT06441643Written as Latanoprost 0.005% Ophthalmic Solution
- MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Nicox Ophthalmics, Inc.NCT04630808Written as Latanoprost 0.005%
- OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese SubjectsCompletedPhase 3Otsuka Beijing Research InstituteNCT05583474Written as 0.005% Latanoprost
- A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen SASNCT04133311Written as Xalatan®
- Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular HypertensionSuspendedPhase 1/2JeniVision, Inc.NCT04761705Written as Latanoprost 0.005% Ophthalmic Solution
- A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT02981446Written as Latanoprost ophthalmic solution
- A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT05495061Written as Latanoprost ophthalmic solution 0.005%
- Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2Nicox Ophthalmics, Inc.NCT03657797Written as Latanoprost 0.005%
- Nailfold Capillary Blood Flow With Latanoprost BunodCompletedPhase 4Icahn School of Medicine at Mount SinaiNCT03949244Written as Latanoprost 0.005%
- African Glaucoma Laser TrialWithdrawnPhase 4West Virginia UniversityNCT03648229Written as Latanoprost ophthalmic solution
- A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In PatientsCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00856622Written as latanoprost 0.005% ophthalmic solution
- A Study of Glaucoma or Ocular Hypertension in Patients Within the United StatesCompletedPhase 3Pfizer's Upjohn has merged with Mylan to form Viatris Inc.NCT00800267Written as latanoprost 0.005%
- Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved LatanoprostCompletedPhase 4CHA UniversityNCT04743622Written as Xalatan
- Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular HypertensionCompletedPhase 1/2Novartis PharmaceuticalsNCT00846989Written as Latanoprost
- POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle GlaucomaCompletedPhase 2Peregrine OphthalmicNCT02466399Written as Latanoprost ophthalmic solution
Showing 20 of 64.
Codes
What other systems call Latanoprost · ClinicalTrials.gg INT006705
- MeSH (NLM) D000077338LatanoprostConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6Z5B6HVF6OLATANOPROSTConfirmed FDA, NLM, Wikidata
- RxNorm 43611Confirmed FDA, Wikidata
- Wikidata Q634959latanoprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29151LatanoprostOne source FDA
- DrugBank DB00654One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077338 | Latanoprost | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6Z5B6HVF6O | LATANOPROST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 43611 | — | Confirmed FDA, Wikidata |
| Wikidata | Q634959 | latanoprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29151 | Latanoprost | One source FDA |
| DrugBank | DB00654 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.